E-cadherin by IHC

Alphabetical Test listing

E-cadherin by IHC-12376 - Technical only, 12379 - Technical & interpretation

  
E-cadherin by IHC
  
12376 - Technical only, 12379 - Technical & interpretation
  
LAB12376
LAB12379
  
  • The primary use for this antibody is in distinguishing between invasive and in-situ breast carcinomas
  • DCIS and infiltrating ductal carcinomas show membrane based staining. LCIS and infiltrating lobular carcinomas usually negative or show weak, non-specific cytoplasmic staining
  • The clinical significance of serum cadherins levels in patients with cancer is not known, but E-Cadherin is elevated in patients with Paget's disease, metastatic melanoma, gastric and bladder cancer
  • E-Cadherin is also elevated in the serum of patients with various skin disorders
  
Tissue
  

Submit a formalin-fixed, paraffin-embedded tissue

  

Formalin-fixed, paraffin-embedded (FFPE) tissue block

  

FFPE tissue section mounted on a charged, unstained slide

  

Ambient (preferred)

  
  • Unlabeled/mislabeled block
  • Insufficient tissue
  • Slides broken beyond repair
  
AHL - Immunohistochemistry
  
Mo - Fr
  
1 - 2 days
  

Immunohistochemical staining and microscopic examination

  

If requested, an interpretive report will be provided

  

Specifications

  • E-Cadherin is a Ca++ dependent trans-membrane cell-cell adhesion protein, which functions as a tumor suppressor
  • E-Cadherin is expressed by many different types of tumors, and can also be found in the serum in patients with various malignancies
  • In breast tumors, E-Cadherin has been shown to be present in invasive ductal carcinomas of the breast, and is present in DCIS, regardless of the lesion grade
  • However, E-Cadherin staining is frequently lost in invasive and in-situ lobular breast carcinomas
  • This antibody has recently been used in differentiating between DCIS and LCIS

Staining pattern

  • Strong, membrane based staining

References

  1. Lehr HA et al: Cytokeratin 8 immunostaining pattern and E- Cadherin expression distinguish lobular from ductal breast carcinoma. Am J Clin Pathol 2000; 114:190-196.
  2. Jacobs TW et al: Carcinomas in situ (CIS) of the breast with indeterminate features: Role of E-Cadherins staining in categorization. Lab Invest 80:23A, 2000.
  3. Acs G et al: Differential expression of E-cadherins in ductal and lobular carcinoma of the breast. Lab Invest 80:17A, 2000.
  4. Knudsen KA et al: Lack of correlation between serum levels and of E- and P-cadherins fragments and the presence of breast cancer.
  5. 7.11.018. Epub 2008 May 20.
  
88342 - 1st stain
88341 - each additional stain
  
06/21/2017
  
10/17/2018
  
10/02/2020